Lynch syndrome, also known as hereditary nonpolyposis colon cancer (HNPCC), is the most common known genetic syndrome for colorectal cancer (CRC 
INTRODUCTION

MLH1
(MIM] 120436) and MSH2 (MIM] 609309) mutations underlie 90% of Lynch syndrome or hereditary nonpolyposis colon cancer (HNPCC). The clinical phenotype of MLH1/MSH2 mutations ranges from Bethesda guidelines (BG) [Rodriguez-Bigas et al., 1997; Umar et al., 2004 ] to familial colorectal cancer (CRC) (defined as proband plus either one affected first-degree relative or two affected second-degree relatives), and even sporadic CRC . Part of the variation in clinical phenotypes is attributable to missense mutations. A total of 24% of Lynch syndrome mutations are missense . There is widespread consensus among cancer geneticists that distinguishing deleterious from neutral variants is challenging. Supporting evidence that a missense variant is functionally relevant and confers risk includes microsatellite instability (MSI), cosegregation with affected relatives, tumor immunohistochemistry (IHC), biochemical analyses, and case-control studies. Many missense variants have minimal or conflicting supporting evidence (termed variants of uncertain significance [VUS] ).
SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and PolyPhen (http:// coot.embl.de/PolyPhen) are bioinformatic algorithms that use evolutionary history and physicochemical parameters to interpret missense variants. They are 60 to 80% accurate in test studies [Chan et al., 2007; Chasman and Adams, 2001; Ng and Henikoff, 2001; Raevaara et al., 2005; Sunyaev et al., 2000b Sunyaev et al., , 2001 Xi et al., 2004] . A recent study directly compared these, and other, algorithms, to interpret missense variants in several proteins, including MLH1 and MSH2 [Chan et al., 2007] . This study confirmed a high predictive value for algorithms that use evolutionary sequence conservation, with or without considering protein structural change, to predict the clinical consequences of missense variants [Chan et al., 2007] . A newer algorithm, multivariate analysis of protein polymorphisms (MAPP) [Stone and Sidow, 2005] , utilizes a similar approach and is more accurate. Importantly, MAPP can be customized for specific proteins. We have therefore optimized MAPP specifically for MLH1/MSH2 and developed MAPP-mismatch repair (MMR), an application that distinguishes MLH1/MSH2 deleterious variants from neutral variants more effectively than any other current computational approach.
METHODS
Database of MLH1/MSH2 Missense Variants
We compiled a database of all known MLH1/MSH2 missense variants (Supplementary Table S1 ; available online at http:// www.interscience.wiley.com/jpages/1059-7794/suppmat) from: the Mismatch Repair Genes Variant Database (www.med.mun.ca/ mmrvariants); InSIGHT (www.insight-group.org); additional MEDLINE articles [Blasi et al., 2006; Lipkin et al., 2004] ; Database of Single Nucleotide Polymorphisms (dbSNP, NCBI; www.ncbi.nlm.nih.gov); Myriad Genetics, unpublished data; Seattle SNP Discovery Project (SeattleSNPs; http://pga.gs.washington.edu); HapMap (www.hapmap.org); and missense variants from individuals with no personal or family history of cancer. All variants were reviewed and annotated with all supporting data available. Supporting data include: age at first CRC diagnosis, affected relatives with CRC, and missense mutation cosegregation/ linkage, MSI status, IHC status, molecular epidemiology, and/or detailed biochemical functional analysis. Supporting data was used to classify missense variants as deleterious or neutral. Rigorous criteria were used to ascertain definitive classes of deleterious and neutral variants. To ensure specificity of neutral variant classification, any missense variant originally described in a CRC proband was limited to classification as a variant of uncertain significance or deleterious variant. Missense variants classified as deleterious satisfied Z2 of the following criteria: 1) positive segregation analysis in 41 family member with CRC or endometrial cancer, or 2) abnormal result in Z1 of the following biochemical studies: nuclear localization/PMS2 colocalization, protein stability in cell culture, or functional assays; or 3) MSI-H in at least one tumor; 4) IHC-negative status; or 5) molecular epidemiology studies demonstrating significantly increased missense variant frequency in CRC cases vs. controls in Z2 nonoverlapping cohorts. Variants that met only one of these criteria were classified as VUS. Criteria for neutral variants: 1) identification in groups of control subjects for SNP discovery (e.g., dbSNP), or 2) missense variants identified in control subjects with no personal or family history of CRC or endometrial cancer (Table 1) . The entire set of deleterious variants was divided into two independent sets for algorithm training (n 5 24) and validation (n 5 25).
MAPP-MMR is modified from multivariate analysis of protein polymorphisms (MAPP) (http://mendel.stanford.edu/SidowLab/ downloads.html) [Stone and Sidow, 2005] . At each amino acid position in a multisequence alignment of MLH1 or MSH2 orthologs, MAPP-MMR infers the evolutionary relationships of the protein sequence by likelihood analysis. Weights for each sequence position are quantified for the physiochemical properties of all amino acids occurring at that position for the following parameters: hydropathy, polarity, charge, side-chain volume, free energy in a-helix conformation, and free energy in b-sheet conformation. For each physiochemical property parameter at that position, the mean and standard deviation are calculated based on each amino acid appearing in the alignment. The summary of these measures is an estimate of the physicochemical constraint at each position, and a standard normalized score for each new amino acid is calculated using the observed mean and variance for that position. A large standard normalized score indicates that the amino acid analyzed is dissimilar from the amino acids appearing in the ortholog alignment, and hence is more likely to affect protein function. For a more detailed description of the MAPP algorithm, please see Stone and Sidow [2005] .
To develop MAPP-MMR we customized input sequences, evolutionary conservation gap-weight threshold, and impact score threshold. Initially, default parameters for MAPP were used (gap weight threshold 5 50% and impact score threshold 5 5.0 [Stone and Sidow, 2005] ). Sequence alignments and unrooted phylogenetic trees were constructed using ClustalW (www.ebi.ac.uk/Tools/clustalw). Initial training and optimization sequence sets included: 1) all NCBI Blast hits with input MLH1(gi:4557757) and MSH2 (gi:4557761); 2) all unique MLH1/MSH2 orthologs and homologs; 3) MLH1/MSH2 eukaryotic orthologs only; 4) MLH1/MSH2 vertebrate orthologs only; and 5) nonredundant prokaryotic and eukaryotic orthologs. MAPP-MMR scores from these sequence sets were calculated for all missense variants. Accuracy of MAPP-MMR predictions was calculated based on impact scores for the training subset of deleterious variants and all neutral variants. Initially, sequence set ]5 performed optimally and was used for further optimization.
Gap weight represents an important measure of amino acid conservation in a multisequence alignment [Ng and Henikoff, Table S2 ) and eukaryotic orthologs only for domains with 467% gap weight; and 7) nonredundant prokaryotic and eukaryotic orthologs for domains with gap weight o67% and eukaryotic orthologs only for domains with 467% gap weight, and eukaryotic orthologs only for the MLH3/PMS2/PMS1 interaction domain (amino acids 492-680) and the MSH3/MSH6 interaction domain (amino acids 378-625). Sequence set ]7 performed optimally and was used for all further missense variant analysis.
Varying the MAPP-MMR classification threshold from 2.0 to 10.0, we generated a receiver operating characteristic (ROC) curve, and calculated the area under the curve (AUC) to equal 0.945 (Fig.  1 ). This curve identified an optimal threshold of 4.55 for classifying deleterious and neutral variants (Fig. 1 ). All MAPP-MMR training and optimization was carried out on a randomly selected subset of deleterious (n 5 24 of 49) and all neutral variants (n 5 26). The remaining nonoverlapping independent set of deleterious variants (n 5 25) was used for validation of the algorithm (Table 2) . MAPP-MMR code is available upon request from the authors.
In Silico Analyses
All MAPP-MMR, SIFT [Ng and Henikoff, 2001 and PolyPhen [Ramensky et al., 2002; Sunyaev et al., 2001] comparisons used input sequences MLH1 (gi:4557757), MSH2 (gi:4557761), and Supplementary Table S1 missense variants. Because they are used in subsequent analyses, Supplementary Table S1 missense variants carried in families from the Creighton Registry and familial CRC subjects were excluded from MAPP-MMR comparisons with SIFT/PolyPhen. Thresholds of o0.05 (SIFT) and 42.0 (PolyPhen) were used to classify deleterious variants and Z0.05 (SIFT) and r2.0 (PolyPhen) to classify neutral variants Henikoff, 2001, 2002; Ramensky et al., 2002; Sunyaev et al., 2000a Sunyaev et al., , 2001 . Chi-squared tests compared significant differences in classification accuracy for sensitivity/ specificity/negative predictive value (NPV)/positive predictive value (PPV) of missense deleterious and neutral variants. MAPP-MMR scores for all possible MLH1/MSH2 amino acid substitutions are publicly available in a web-based format (www.healthaffairs.uci.edu/biochem/faculty/lipkin.html).
Creighton Hereditary Cancer Institute Registry Families
A total of 21 families previously evaluated in the Creighton Hereditary Cancer Institute (HCI) Cancer Genetics Clinic with identifiable deleterious MLH1/MSH2 missense variants were studied. All families meet revised BG and have been previously reported [Lynch, 1999; Peltomaki et al., 2004; Stella et al., 2001; Wagner et al., 2003; Watson et al., 2003 Watson et al., , 2004 .
MSH2 G322D Case^Control Study
For the relatively common missense variant MSH2 G322D, 1,867 CRC case and 1,918 age-, gender-, and ethnically-matched control subjects from the MECC study [Poynter et al., 2005] were genotyped using TaqMan (Applied Biosystems, Foster City, CA) as described [Greenson et al., 2003; Gruber et al., 2002; Shin et al., 2005] (Supplementary Table S3 ).
Familial CRC Subjects
In the Southern California CRC Cohort of CRC subjects younger than age 55 from Orange County, San Diego County, and Imperial County in Southern California [Anton-Culver et al., 2003; Peel et al., 2000] , 142 American CRC probands with familial CRC regardless of MSI status were identified. The clinical and epidemiological features of these subjects are presented in Supplementary Table S4 . From this group, germline DNA biospecimens from 91 individuals were available. MLH1/MSH2 coding exons were sequenced in these 91 individuals for this study.
Control Subject MLH1/MSH2 Sequencing
A total of 65 American control subjects from the University of California (UC) Irvine Environmental Health Effects Study [Bernstein et al., 2004; Semenza et al., 2001] matched to the first 65 of 91 Southern California Colorectal Cancer Cohort Familial CRC probands were sequenced for this study. Control sequencing stopped after the first 65 subjects because of the highly 
Statistical Methods
Mean MAPP-MMR scores were calculated for all groups: deleterious variants, VUS, neutral variants, Creighton HCI families, and familial CRC Cohort. A two-sided Student's t-test and one-way analysis of variance (ANOVA) was used to compare these means. MAPP-MMR performance was compared to that of SIFT and PolyPhen using chi squared analysis. Genotyping for MSH2 G322D was carried out for the entire MECC cohort of 3,785 individuals. Odds ratios were calculated for the entire cohort, cases vs. controls, and adjusted for ethnicity and family history. The frequency of MAPP-MMR predicted deleterious and truncating mutations was compared in the American Familial CRC cohort using the chi-squared test.
RESULTS
We compiled a database of all known MLH1/MSH2 missense variants (n 5 301) and used rigorous criteria to classify them into three categories: A) deleterious variants (n 5 49); B) VUS (n 5 226); or C) neutral variants (n 5 26) (Supplementary Table   S1 ; Table 1 ). We used MAPP-MMR to predict the impact of these missense variants (Fig. 2) . Higher MAPP-MMR scores correlate with greater predicted deleterious impact on protein function. Consistent with this observation, the mean MAPP-MMR score for deleterious variants is higher than VUS or neutral variants (16.5 vs. 10.8 vs. 3.5, Po0.001, one-way ANOVA) (Fig. 3) . Similarly, MAPP-MMR scores are inversely correlated with CRC age of onset, which is younger in carriers of deleterious variants (P 5 0.0006, two-sided Student's t-test with Welch correction).
The MAPP-MMR missense variant scores divide into three primary distributions. A total of 96% of neutral variants cluster in the lowest scoring distribution and 94% of deleterious variants cluster in the higher two distributions, while SIFT/PolyPhen scores for deleterious and neutral variants overlap significantly. The optimal MAPP-MMR threshold to segregate deleterious and neutral variants is 4.55 (Fig. 1) . We directly compared the accuracy of MAPP-MMR with SIFT and PolyPhen to classify MLH1/MSH2 deleterious and neutral variants. Initially, an exploratory set of 24 deleterious variants was used to develop MAPP-MMR. For validation of the MAPP-MMR algorithm, a direct comparison was made between SIFT, PolyPhen, and MAPP-MMR accuracy on a second, nonoverlapping set of 25 deleterious variants. In this independent set, MAPP-MMR outperformed SIFT and PolyPhen with improved sensitivity, specificity, PPV, and NPV. On the entire set of deleterious variants, the accuracy of classification for MAPP-MMR was significantly higher, (sensitivity, 94%; specificity, 96%; PPV, 98%; NPV, 89%), than SIFT or PolyPhen ( more validating criteria are used to classify deleterious variants more rigorously, MAPP-MMR sensitivity increases at the expense of statistical power ( Table 2 ). The BG and bioinformatic models incorporate past medical history (PMH), family medical history (FMH), and MSI/IHC to estimate risk of carrying a deleterious variant, but do not interpret missense variants subsequently identified. We reasoned that if MAPP-MMR is accurate in missense variant interpretation, MAPP-MMR predicted deleterious variants should be found in families at high risk of carrying deleterious variants by these models. After development, and to further test its accuracy, we used MAPP-MMR to classify missense deleterious variants in 21 families with MLH1/MSH2 missense variants evaluated for Lynch syndrome by Henry Lynch. These were excluded from the model development stage (Table 4) . Two families carry both missense deleterious variants and genomic deletions, and are discussed separately. For the 19 remaining families with 15 unique variants we applied the identical criteria as above to classify variants incorporating findings regarding the presence/absence of missense variants in other family members and MSI/IHC. A total of 17 families had missense variants classified as deleterious and two families as VUS (Table 4) . Using the identical approach and parameters employed to analyze the missense variant database with these 19 families, MAPP-MMR had 100% accuracy in correct classification (17 deleterious variants and two VUS) (Table 4) .
To prospectively test MAPP-MMR classification accuracy we analyzed MSH2 G322D. This missense variant has been interpreted by different groups alternately as deleterious [Liu et al., 1996; Maliaka et al., 1996] or benign [Froggatt et al., 1996; Herfarth et al., 1997] (In InSiGHT MSH2 G322D is listed in both pathogenic and nonpathogenic categories). MSH2 G322D's score is 3.24 (predicted neutral variant). To rigorously test MAPP-MMR's classification, we quantified MSH2 G322D frequency in 3,785 population-based CRC cases and matched controls (Supplementary Table S3 Next, we applied MAPP-MMR to quantify more precisely the contribution of MLH1/MSH2 missense deleterious variants and truncating mutations to familial CRC (defined as proband and one first degree relative or two second degree relatives with CRC). A total of 15 to 20% of all CRC is familial [Burt and Peterson, 1996; Burt, 1997] , and many of these probands do not meet BG [Barnetson et al., 2006; Hampel et al., 2005a Hampel et al., , 2005b Pinol et al., 2005] . To prospectively test MAPP-MMR's predictive ability, we sequenced germline MLH1/MSH2 from 91 familial CRC subjects from Southern California [Peel et al., 2000] . In addition to 34 predicted neutral variants and one truncating mutation, MAPP-MMR predicted 10 deleterious missense variants in familial CRC subjects (12.1%) ( Table 5) . Two (MSH2 T552P and MLH1 T117 M) were previously identified as deleterious variants (Supplementary Table S1 ). Tumor location is known for 8 out of 10 subjects. CRCs are right-sided in 7 out of 8 (87%). MSI status was performed on six subjects, and 4 out of 6 are MSI-L or MSI-H (66%). For three familial CRC probands, a DNA sample from a first degree relative with CRC was available, and in 3 out of 3 cases the predicted missense variant cosegregated. Therefore, MAPP-MMR identified patients enriched in Lynch syndrome features, and the predicted deleterious variants cosegregated in affected siblings. For comparison, we sequenced 65 controls matched to the above American Familial CRC cases and identified no truncating or MAPP-MMR predicted MLH1/MSH2 deleterious variants (P 5 0.003, chi-squared).
As expected, MAPP-MMR predicted neutral variants were found in sequencing of both familial CRC cases and controls (Supplementary Table S4A ). MLH1 I219 V was found at similar frequencies in case and controls (P40.05, chi-squared) and the only predicted neutral variant with allele frequency high enough for analysis for molecular epidemiology. The remaining predicted neutral variants were evaluated in aggregate and had similar frequencies in cases and controls (P40.05, chi-squared). These patients had clinical features similar to those seen in sporadic CRC (Supplementary Table S4B ). The mean MAPP-MMR score is 13.5 for familial CRC subjects with predicted deleterious variants. Consistent with the clinical phenotype, the familial CRC mean MAPP-MMR score is less than that of Lynch syndrome missense deleterious variants (16.5) and higher than neutral variants (3.5, P 5 0.038, two-sided Student's t-test) (Fig. 3) . (Table 4 ; Families 1^19), familial CRC subjects (Table 5) , deleterious variants, VUS, and neutral variants (SupplementaryTable S1; Table 1 ) are indicated. Ã P values for comparison with MAPP-MMR using chi-square test are noted in parentheses. The criteria for missense deleterious and neutral variants are de¢ned inTable 1, and the list of all variants is presented in SupplementaryTable S1.
DISCUSSION
More than 300 unique MLH1/MSH2 missense variants have been reported. There is consensus among cancer geneticists that interpretation of missense variants is challenging. MSI analysis is important, with an estimated 80% sensitivity and 90% specificity for detecting MLH1/MSH2 mutations [Yan et al., 2000] . However, MSI testing is expensive and tumors sometimes cannot be obtained. IHC is useful, but deleterious missense variants can cause nonfunctional proteins that are still expressed and scored as wild type in this assay [Liu et al., 1999; Wahlberg et al., 2002] . Molecular epidemiology is helpful, but most missense variants are extremely rare. Biochemical analysis of missense variants is important, but the cost is prohibitive for clinical application. A recent study compared head-to-head current computational algorithms designed to interpret missense variants in several proteins that are associated with human genetic disease [Chan et al., 2007] . This comparison included 28 MLH1 and 21 MSH2 missense variants and confirmed a high predictive value for algorithms that use evolutionary sequence conservation (with or without incorporating protein structural change) to predict the clinical consequences of missense variants [Chan et al., 2007] . A newer algorithm, MAPP, utilizes a similar approach and is more accurate [Stone and Sidow, 2005] . Importantly, MAPP can be customized for specific proteins. We have therefore optimized MAPP specifically for MLH1/MSH2 and developed MAPP-MMR for missense variant interpretation in these clinically important genes.
To develop and validate our variant prediction algorithm we constructed a database of all known MLH1/MSH2 variants and all publicly available supporting evidence, in numerous cases supplemented by additional unpublished data. As comprehensive evidence is not systematically reported in the literature for all variants, 75% of variants were classified as VUS. This point highlights the importance of reporting as much clinical, epidemiologic, and biochemical data available as possible on new variants.
In general, variants with more independent lines of evidence supporting deleterious effects are more likely to be deleterious. While the same trend is seen whether MAPP-MMR uses 1, 2, or 3 criteria to classify variants as deleterious or neutral, to decrease false positives MAPP-MMR was trained and validated on deleterious variants meeting Z2 criteria (Table 1) . For variants meeting Z2 criteria, 94% of deleterious variants are correctly classified and 6% are incorrectly classified as neutral variants (Table 1) . For variants meeting Z3 criteria, 100% of deleterious variants are correctly classified. However, the number of VUS increases. Therefore, clinicians must use their individual judgment as to how they want to combine available evidence with MAPP-MMR scores in their interpretation of novel MLH1/MSH2 missense variants seen in the clinic in the future. It is also important to note that higher MAPP-MMR scores correlate with greater deleterious impact, a parameter that can also be incorporated into clinical interpretation of novel variants. The overall accuracy of MAPP-MMR is 94.6%. However, for variants with borderline scores of 3.0 to 5.0 the overall accuracy is only 88% (15 of 17 variants). Therefore we have made added a provisional cautionary warning to these variants as ''borderline.'' Missense variants can impair proteins not only by affecting structure-function, but also at the DNA level because of mRNA splicing. Based on evolutionary conservation, MAPP-MMR identified several missense variants as deleterious mutations whose mechanism is impaired splicing. Splicing is an important mechanism because biochemical approaches expressing MLH1/MSH2 variant cDNAs will misclassify deleterious splicing mutations as neutral variants. Similarly, because some biochemical assays express MLH1/MSH2 in yeast and insect cells, posttranslational modification processing signals conserved in mammals may similarly be misclassified using only the biochemical approach.
For VUS, MAPP-MMR generates hypotheses as to which are neutral and which are deleterious (Supplementary Table S5 ). MSH2 G322D is common enough that we were able to test its MAPP-MMR classification using molecular epidemiology. Unfortunately, most of the remaining VUS are rare and not amenable to this approach.
The development of risk prediction models based on PMH and FMH to predict the probability of detecting Lynch syndrome mutations is exciting [Balmana et al., 2006; Barnetson et al., 2006; Chen et al., 2006; Wijnen et al., 1998 ]. However, these algorithms can cause missense variant interpretation biases. In the example of MLH1 T117 M (Table 4) , its high MAPP-MMR score (21.05) provided useful confirmatory evidence that it is truly a deleterious variant. While additional supporting evidence from the literature exists for MLH1 T117 M, for many missense mutations supporting evidence is inadequate (Supplementary Table S5 ) and MAPP-MMR scores may be the only information available. Finally, MLH1/MSH2 variants identified in high-risk probands may cause their overinterpretation as deleterious. For example, variants inconsistent with highly penetrant Lynch syndrome mutations (MSH2 N583S and MLH1 E578G) and MSH2 genomic deletions were identified in two families (Table 4) . Both families were correctly classified by BG as high-risk for a deleterious variant. However, these algorithms cannot distinguish whether the variant or genomic deletion is the causative deleterious mutation. MAPP-MMR predicted MSH2 N583S as benign (score 2.42), and MLH1 E578G (score 4.85) as a borderline deleterious variant. In both families the MAPP-MMR scores are inconsistent with the probands' CRC onset at 35 and 39 years of age and affected first degree relatives and predicted the existence of a cryptic mutation not identified by MLH1/MSH2 sequencing, such as a genomic deletion. Because of cost, many laboratories will serially sequence MLH1/MSH2 first, and perform MLPA/Southern analysis only if no mutation is identified. Therefore, it is anticipated that in some patients VUS will be interpreted as mutations and additional analyses foregone unless the missense mutation's predicted impact is assessed. MAPP-MMR may be particularly useful in these situations. Recently, similar approaches to combine mutation risk prediction and missense variant classification have recently been developed for BRCA1/BRCA2 [Chenevix-Trench et al., 2006; Goldgar et al., 2004; Phelan et al., 2005; Wu et al., 2005] . As with these BRCA1/BRCA2 missense mutation classification algorithms, future studies will be required to validate MAPP-MMR with additional datasets, and to define the optimal combination of mutation risk prediction models and MAPP-MMR, for the highest accuracy of missense variant classification.
